Vanguard Capital Management
CLDI icon

Vanguard Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

Vanguard Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.34K Hold
1,594
– – ﹤0.01% 4070
2026
Q1 		$6.1K Buy
+1,594
New +$19.2K ﹤0.01% 4033

Other funds holding CLDI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management's CLDI Position: Q2 2026 in Review

Vanguard Capital Management held its Calidi Biotherapeutics (CLDI) position steady in Q2 2026 at 1,594 shares worth $4.34K. The position accounts for ﹤0.01% of the portfolio, ranked #4070.

Vanguard Capital Management first reported a position in CLDI in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.1K in Q1 2026. 23 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

  • Vanguard Capital Management held 1,594 shares of Calidi Biotherapeutics worth $4.34K as of Q2 2026.
  • Vanguard Capital Management left its Calidi Biotherapeutics share count unchanged in Q2 2026.
  • Calidi Biotherapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4070 holding.
  • Vanguard Capital Management first reported a position in Calidi Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Calidi Biotherapeutics position peaked at $6.1K in Q1 2026.
  • 23 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.